6ORY3HGLDWU
5D]LVNRYDOQLþODQHN5HVHDUFKDUWLFOH
8ý,1.29,7267='5$9/-(1-$2752.=$6702
=$17$*21,67,/(9.275,(16.,+5(&(3725-(9
7+(())(&7,9(1(662)75($70(17:,7+/(8.275,(1(
RECEPTOR ANTAGONISTS IN CHILDREN WITH ASTHMA
06OHPQLN8.ULYHF$.RWQLN3LUã
2GGHOHN]DSHGLDWULMR6SORãQDEROQLãQLFD6ORYHQM*UDGHF 6ORYHQM*UDGHF6ORYHQLMD
6OXåED]DSXOPRORJLMR3HGLDWULþQDNOLQLND8QLYHU]LWHWQLNOLQLþQLFHQWHU/MXEOMDQD /MXEOMDQD6ORYHQLMD
.DWHGUD]DSHGLDWULMR0HGLFLQVNDIDNXOWHWD8QLYHU]DY/MXEOMDQL /MXEOMDQD6ORYHQLMD
,=9/(ý(.
,]KRGLãþD =UD]LVNDYRVPRåHOHOLRSUHGHOLWLXþLQNRYLWRVW]GUDYOMHQMDRWURN]DVWPR]DQWDJRQLVWLOHYNRWUL- HQVNLKUHFHSWRUMHY
0HWRGH9GYHOHWQRUHWURVSHNWLYQRUD]LVNDYRVPRYNOMXþLOLYVHRWURNHNLVRVH]DUDGLDNXWQHJDSRVODEãDQMD DVWPH]GUDYLOLQD3HGLDWULþQLNOLQLNLY/MXEOMDQLLQVRRERGSXVWXYGRPDþRRVNUERSUHMHPDOLDQWDJRQLVWH OHYNRWULHQVNLKUHFHSWRUMHY2SUHGHOLOLVPRQMLKRYH]QDþLOQRVWLSRWHNKRVSLWDOL]DFLMHSRWUHERSR]DPHQMDYL ]GUDYLORENRQWUROQHPSUHJOHGXLQNRPSOLDQFRSULL]YDMDQMX]GUDYOMHQMDYGRPDþHPRNROMX
5H]XOWDWL =DUDGLDNXWQHJDSRVODEãDQMDDVWPHVHMHYOHWLK±]GUDYLORRWURNRWURN MH RE RGSXVWX SUHMHPDOR L]NOMXþQR DQWDJRQLVWH OHYNRWULHQVNLK UHFHSWRUMHY 1MLKRYD SRYSUHþQD VWDURVW MH ELODOHWD3ULMHYVDMHGHQRGVWDUãHYLPHODVWPRMHLPHORSRWUMHQRDOHUJLMRQDLQKDODFLMVNH DOHUJHQHDOHUJLMRQDSUHKUDQVNHDOHUJHQHDWRSLMVNLGHUPDWLWLVSHULIHUQRHR]LQR¿OLMRLQ YHþGHMDYQLNRYWYHJDQMD]DDVWPRKNUDWLRWURNMHPHGKRVSLWDOL]DFLMRNLMHWUDMDODSRYSUHþQR GQHYDSRWUHERYDORGRGDWHNNLVLNDYYGLKDQHP]UDNX=GUDYOMHQMH]DQWDJRQLVWLOHYNRWULHQVNLKUHFHSWRUMHY MHELORXþLQNRYLWRSULYNOMXþHQLKRWURNSULSDVPRPRUDOL]GUDYOMHQMHVSUHPHQLWL.RPSOLDQFD MHELOD
=DNOMXþHN$QWDJRQLVWLOHYNRWULHQVNLKUHFHSWRUMHYVRQHVWHURLGQD]GUDYLOD]DSHURUDOQR]GUDYOMHQMHEODJH
DVWPH.RWHGLQR]GUDYLORMLKRELþDMQRSUHGSLãHPRRE]DþHWNX]GUDYOMHQMDSUHGYVHPSULPODMãLKRWURFLKNRW dodatno zdravilo, pa jih uporabimo kadar zdravljenje z zmernimi odmerki inhalacijskih glukokortikoidov QLGRYROMXVSHãQR8VSHãQRVW]GUDYOMHQMDLQNRPSOLDQFDVWDELOLYRSLVDQLUD]LVNDYLYHOLNL
.OMXþQHEHVHGHRWURFLRNXåEDGLKDO]QDþLOQRVWLKRVSLWDOL]DFLMDDQWDJRQLVWLOHYNRWULHQVNLKUHFHS- WRUMHY
ABSTRACT
%DFNJURXQG The aim of the study was to identify whether leukotriene receptor antagonists are effective in WUHDWLQJDVWKPDLQFKLOGUHQ
0HWKRGV $WZR\HDUUHWURVSHFWLYHVWXG\LQFOXGHGDOOFKLOGUHQZLWKDQDFXWHDVWKPDH[DFHUEDWLRQGLVFKDU- JHGIURPWKH8QLYHUVLW\&KLOGUHQ¶V+RVSLWDO/MXEOMDQDZLWKOHXNRWULHQHUHFHSWRUDQWDJRQLVWWKHUDS\:H GH¿QHGWKHLUFOLQLFDOFKDUDFWHULVWLFVOHQJWKRIKRVSLWDOVWD\WKHQHHGIRUDFKDQJHLQWUHDWPHQWDWIROORZXS DQGFRPSOLDQFHZLWKWUHDWPHQW
5HVXOWV FKLOGUHQZHUHKRVSLWDOLVHGEHFDXVHRIDQDFXWHDVWKPDH[DFHUEDWLRQEHWZHHQDQG ZHUHWUHDWHGZLWKOHXNRWULHQHUHFHSWRUDQWDJRQLVWVDORQHDWGLVFKDUJH7KHLUPHDQDJHZDV
\HDUV,QRIWKHVHSDWLHQWVRQHRIWKHSDUHQWVKDGDVWKPDZHUHDOOHUJLFWRDQLQKDODWRU\DOOHUJHQ WRDQDOLPHQWDU\DOOHUJHQKDGDWRSLFGHUPDWLWLVHRVLQRSKLOLDDQGKDGPRUHWKDQRQH ULVNIDFWRUIRUDVWKPDQHHGHGR[\JHQVXSSOHPHQWDWLRQ7KHPHDQGXUDWLRQRIKRVSLWDOLVDWLRQZDV GD\V7KHWUHDWPHQWZDVHIIHFWLYHLQZKLOHLQDFKDQJHLQWUHDWPHQWZDVUHTXLUHG&RPSOLDQFH ZDV
&RQFOXVLRQV Leukotriene receptor antagonists are non-steroidal drugs, which are suitable for oral treat- PHQWRIPLOGDVWKPDDQGDVDQDGGRQWKHUDS\ZKHQWUHDWPHQWZLWKLQKDOHGFRUWLFRVWHURLGVDORQHLVLQVXI¿- FLHQW,QWKHSUHVHQWHGVWXG\WKHHIIHFWLYHQHVVRIWUHDWPHQWDQGFRPSOLDQFHWRWKHUDS\ZHUHKLJK
.H\ZRUGVFKLOGUHQDLUZD\LQIHFWLRQFKDUDFWHULVWLFVKRVSLWDOLVDWLRQOHXNRWULHQHUHFHSWRUDQWDJR- QLVWV
892'
$VWPD MH QDMSRJRVWHMãD NURQLþQD EROH]HQ RWURN Sprejemi v bolnišnico zaradi astme so pri otrocih, PODMãLKRGOHWSHWNUDWSRJRVWHMãLNRWSULRGUDVOLK SULRWURFLKYVWDURVWL±OHWSDGYDNUDWSRJRVWHM- ãL NRW SUL RGUDVOLK $QWDJRQLVWL OHYNRWULHQVNLK UHFHSWRUMHY$/75VRHGLQDSHURUDOQD]GUDYLOD]D SUHYHQWLYQR ]GUDYOMHQMH DVWPH (GLQL SUHGVWDYQLN
$/75NLJDXSRUDEOMDPRY6ORYHQLMLMHPRQWHOX- NDVW]GUDYLORNLJDMH$PHULãNDDJHQFLMD]DKUDQR LQ ]GUDYLOD DQJO )RRG DQG 'UXJ $GPLQLVWUDWLRQ )'$ UHJLVWULUDOD ]D ]GUDYOMHQMH DVWPH LQ DOHUJLM- VNHJD ULQLWLVD 0RQWHOXNDVW MH VSHFL¿þHQ VHOHNWLY- ni antagonist cisteinil-levkotrienskih receptorjev, ki zmanjšuje vnetje in upor v dihalnih poteh ter s WHP SUHSUHþXMH EURQKRNRQVWULNFLMR 3R GR
sedaj objavljenih raziskavah naj bi bil montelukast NOMXEGREULWHRUHWLþQLRVQRYLXþLQNRYLWOHSULPDQM- ãLQLRWURN]DVWPR6SHFL¿þQLKR]QDþHYDOFHYNLEL QDP SRPDJDOL GRORþLWL SRSXODFLMR SUL NDWHUL ERGR
$/75XþLQNRYLWLåDOãHQHSR]QDPR7DNRVHSUL SUHGSLVRYDQMX ]GUDYLOD ]DQDãDPR WXGL QD NOLQLþQH izkušnje ob upoštevanju, da je zanesljivo diagnozo DVWPDSULRWURFLKPODMãLKRGOHWWHåNRSRVWDYLWL
0(72'(,1%2/1,.,
Retrospektivno smo pregledali popise otrok, ki so ELOLYOHWLK±KRVSLWDOL]LUDQLQD3HGLDWULþQL NOLQLNLY/MXEOMDQLLQVRELOLRGSXãþHQL]GLDJQR]R
DNXWQRSRVODEãDQMHDVWPH3ULL]ELULEROQLNRYVPR XSRUDELOL SURJUDP ,63(. ,QIRUPDFLMVNL VLVWHP 3HGLDWULþQH NOLQLNH WHU L] SRSLVRY EROQLNRY ]EUDOL QDVOHGQMH SRGDWNH VWDURVW OHWQL þDV KRVSLWDOL]D- cije, vzrok poslabšanja, potreba po zdravljenju z dodatkom kisika v vdihanem zraku, trajanje hospi- talizacije, zdravljenje s sistemskim glukokortiko- LGRP GUXåLQVND DQDPQH]D DOHUJRORãNR WHVWLUDQMH LQGLIHUHQFLDOQDNUYQDVOLND,]]DSLVQLNDRESUYHP kontrolnem pregledu v pulmološki ambulanti smo RFHQLOLDOLMHELOR]GUDYOMHQMHXþLQNRYLWRLQNDNãQR ]GUDYOMHQMH MH SUHGYLGHQR Y QDGDOMHYDQMX $/75 VWDOQR$/75LQWHUPLWHQWQRDOL]DPHQMDYD]DLQKD- ODFLMVNLJOXNRNRUWLNRLG,*.R]GRGDWHN,*.3UL RWURFLK NL VR SRWUHERYDOL EROQLãQLþQR ]GUDYOMHQMH SUHGQDþUWRYDQLPDPEXODQWQLPNRQWUROQLPSUHJOH- GRPVPRSRGDWNHSRY]HOLL]]DNOMXþQHRGSXVWQLFH L]EROQLãQLFH
5(=8/7$7,
9OHWLK±VHMHQD3HGLDWULþQLNOLQLNLY/MX- bljani zaradi akutnega poslabšanja astme zdravil RWURNRWURNMHRERGSXVWXSUHMHPDOR L]NOMXþQR$/75 0HGLDQD VWDURVWL RWURN NL VR RE RGSXVWXSUHMHPDOLL]NOMXþQR$/75MHELODOHWD
UD]SRQPHVHFHYGROHW*OHGHQDPHGLDQR VWDURVWLMHELODYHþNRWSRORYLFDRWURNYSUHGãROVNHP REGREMXRWURNNLVRRERGSXVWXSUHMHOL$/75 VHMH]GUDYLORYQH]LPVNLKPHVHFLK6OLND 9MHELODY]URNSRVODEãDQMDRNXåEDGLKDORG WHJDYLUXVQLKRNXåEDWLSLþQLKSOMXþQLF SRY]URþHQLK]EDNWHULMR0\FRSODVPDSQHXPRQLDH, LQEDNWHULMVNLKSOMXþQLF9VRELOHY]URN SRVODEãDQMD DOHUJLMH LQ NRPELQDFLMH DOHUJLMD ]RNXåERWHUWHOHVQLQDSRU]RNXåER 9YHþLQLSULPHURYVPR]$/75]GUDYLOLSRVODEãD- QMDNLMLKMHSRY]URþLOHQGHMDYQLNOHYMHELO vzrok poslabšanja opredeljen s kombinacijo dveh GHMDYQLNRY6OLND1DMSRJRVWHMãLYLUXVQLSRY]UR- þLWHOMNLVPRJDGRND]DOLL]EULVDQRVQHJDåUHOD, je ELOULQRYLUXVVOHGLOLVRHQWHURYLUXVLLQ RVWDOLYLUXVL569ERNDYLUXVPHWDSQHYPRYLUXVLQ RVWDOLYLUXVQLKRNXåEHWLRORãNRQLVPRXVSHOL RSUHGHOLWL
Dodatek kisika v vdihanem zraku je potrebovalo YVHKRWURNNLVRVHRERGSXVWXL]EROQLãQL- FH ]GUDYLOL ]$/75 2VWDOLK MH LPHOR EODåMR REOLNREROH]QLLQGRGDWNDNLVLNDQLVRSRWUHERYDOL9 SRYSUHþMXVRELOLRWURFLKRVSLWDOL]LUDQLGQHYDLQ VRGRELOLRGPHUNDVLVWHPVNHJDNRUWLNRVWHURLGD
6OLND'HOHåKRVSLWDOL]LUDQLKRWURNJOHGHQDOHWQLþDV )LJXUH3HUFHQWDJHRIKRVSLWDOL]HGFKLOGUHQDFFRUGLQJWRWKH season.
6OLND3RVODEãDQMHDVWPHJOHGHQDY]URN )LJXUH&DXVHVRIDVWKPDH[DFHUEDWLRQ
QD KRVSLWDOL]DFLMR 3UL RWURN RWURN VPR RSUDYLOL DOHUJRORãNR WHVWLUDQMH SUL RWURN VR ELOL NRåQL WHVWL QHJDWLYQL SUL RVWDOLK RWURNSDSR]LWLYQL3ULRWURNVRDOHUJLMR SRWUGLOLåHVSUHGKRGQLPLDOHUJRORãNLPLWHVWL RWURNMHLPHORRGSUHMQHJDWLYHQUH]XOWDWNRåQLK WHVWRYRWURFLSDVHQLQLNROLDOHUJRORãNRWH- VWLUDOR6NRUDMWUHWMLQDRWURNMHLPHODDOHUJLMRQDSU- ãLFRVOHGLMRDOHUJLMDQDWUDYHLQåLWD WUDYQHSHORGHGUHYHVQHSHORGHPD- þMRGODNRMDMFDSDVMRGODNR SOHYHOHDUDãLGHLQNUDYMHPOHNR 'LIHUHQFLDOQRNUYQRVOLNRVPRGRORþLOLSULRWUR- FLK 2G WHK MH LPHOR RWURN SR- YLãDQRãWHYLORHR]LQR¿OFHYYSHULIHUQLNUYLDOL YHþ3ULRWURFLKVPRGRORþLOLYUHGQRVWLFHORNXSQLK ,J(SULVRELOHYUHGQRVWLSRYLãDQH3UL RWURFLKMHYVDMHGHQRGVWDUãHYMHLPHODVWPR 7DEHOD
3RRGSXVWXL]EROQLãQLFHVPRSULRWURFLK ODKNRQDGDOMHYDOL]REUDYQDYR3ULYVHKVPRRFHQLOL XþLQHN]GUDYOMHQMD]$/75RENRQWUROQHPSUHJOH- GXDOLSRQRYQLEROQLãQLþQLREUDYQDYL3ULRVWDOLK XþLQNRYLWRVWL]GUDYOMHQMDQLVPRPRJOLRFH- QLWLVDMQLVRSULãOLQDNRQWUROQLSUHJOHGR]MLKYRGL SXOPRORJ]XQDM3HGLDWULþQHNOLQLNH2GRWURNMH ELORRWURNRE]GUDYOMHQMX]$/75EUH]
SRVODEãDQM SUL RWURN SD VPR PRUDOL ]GUDYOMHQMH VSUHPHQLWL 2E VSUHPHPEL ]GUDYOMHQMD VPR XSRãWHYDOL QDþHOD VWRSHQMVNHJD ]GUDYOMHQMD LQ
SRXNLQLWYL$/75SUHGSLVDOL,*.3ULGYHKRWURFLK VPR]DUDGLYVDMHQHJDKXMãHJDSRVODEãDQMDLQ SRJRVWLKYPHVQLKSRVODEãDQMGRGDOL,*.LQ]]GUD- YOMHQMHP]$/75QDGDOMHYDOLWRUHMSUHãOLQDVWRSQMR ]GUDYOMHQMDDVWPHRWURNMHELORREUH- GQHP]GUDYOMHQMX]$/75EUH]SRVODEãDQM]DWRVPR svetovali intermitentno nadaljevanje zdravljenja z
$/753ULGYHKRWURFLKVPR]DUDGLY]WUDMDQMD WHåDY RE LQWHUPLWHQWQHP MHPDQMX$/75 VYHWRYDOL UHGQR MHPDQMH 3UL RWURFLK NL VR ELOL RE ]GUDYOMHQMX]$/75EUH]SRVODEãDQMVPRVYHWRYDOL SUHKRGQR XNLQLWHY ]GUDYLOD þH] SROHWMH LQ SRQRYþH] SROHWMH LQ SRQRYin ponov- QRXYHGERREPRUHELWQHPSRVODEãDQMXRWURNRP VPR]DUDGLGREUHJDNOLQLþQHJDXþLQNDVYHWR- YDOLGD]UHGQLPMHPDQMHPQDGDOMXMHMR.RPSOLDQ- FDSUL]GUDYOMHQMX]$/75MHELOD
RAZPRAVLJANJE
*ODYQD]QDþLOQRVWDVWPHMHNURQLþQRYQHWMHGLKDOQLK SRWL &LVWHLQLOVNL OHYNRWULHQL VR SRPHPEQL YQHWQL PHGLDWRUML3RY]URþDMREURQKRNRQVWULNFLMRSRYHþD- MRL]ORþDQMHVOX]LYGLKDOQLKSRWHKSRYHþDMRåLOQR SUHSXVWQRVWLQPLJUDFLMRHR]LQR¿OFHYYGLKDOQHSRWL WHU SRVSHãXMHMR SUROLIHUDFLMR JODGNLK PLãLF$/75 preko kemijskih reakcij blokirajo delovanje cistei- QLOVNLKOHYNRWULHQRY/7&/7'LQ/7(LQWDNR zmanjšujejo vnetje, medtem ko glukokortikoidi sin- WH]HFLVWHLQLOVNLKOHYNRWULHQRYQHEORNLUDMR
7DEHOD/DVWQRVWLRWURNYNOMXþHQLKYUD]LVNDYR 7DEOH&OLQLFDOIHDWXUHVRIFKLOGUHQLQFOXGHGLQWKHVWXG\
Dejavnik tveganja 2GVWRWHN 1
SR]LWLYQDGUXåLQVNDDQDPQH]D
SUHREþXWOMLYRVWQDSUHKUDQVNHDOHUJHQH
SUHREþXWOMLYRVWQDHQHJDDOLYHþLQKDODWRUQLKDOHUJHQRY
atopijski dermatitis
SHULIHUQDHR]LQR¿OLMD
YHþGHMDYQLNRYWYHJDQMDKNUDWL
0RQWHOXNDVWEORNLUDGHORYDQMHOHYNRWULHQD'LQVH- NXQGDUQLKOLJDQGRY/7&LQ/7(QDFLVWHLQLOVNHP OHYNRWULHQVNHP UHFHSWRUMX &\V/7 Y SOMXþLK LQ EURQKLK8þLQHNPRQWHOXNDVWDnastopi zelo hitro SRRGPHUMDQMXLQWUDMD±XU=DWRMHSULPHUHQ za zdravljenje astme, ki se poslabša predvsem ob DNXWQLK YLUXVQLK RNXåEDK GLKDO WL LQWHUPLWHQWQD DVWPD
3UHKRGQR LQ SRQDYOMDMRþH VH SLVNDQMH RE RNXåEDK GLKDO MH SUL PDMKQLK RWURFLK SRJRVWR =DWR MH SR- QDYOMDMRþHVHSUHKRGQRSLVNDQMHHQDL]PHGQDMSR- gostejših diferencialnih diagnoz astme pri otrocih, PODMãLK RG OHW ,]VOHGNL HSLGHPLRORãNLK UD]L- VNDYNDåHMRGDMHYY]URNSRVODEãDQMDDVWPH SULRWURFLKYLUXVQDRNXåEDGLKDO
Pri postavitvi diagnoze astma pri otroku, mlajšem RGOHWVLSRPDJDPR]QDSRYHGQLPLQGHNVRP]D DVWPRDQJO$VWKPD3UHGLFWLYH,QGH[$3,3R]L- WLYQDYUHGQRVW$3,LPDRGVWRWQRSR]LWLYQRQDSR- YHGQRYUHGQRVWLQRGVWRWQRVSHFL¿þQRVW]DQDSR- ved verjetnosti, da bo otrok v šolskem obdobju imel DVWPR 9UHGQRVW $3, MH SR]LWLYQD þH LPD RWURN PODMãL RG OHW Y HQHP OHWX RSD]RYDQMD YVDMštiri epizode piskanja v prsih ter vsaj en veþML dejavnik tveganja za astmo ali dva manjša dejavnika tvega- QMD]DDVWPR0HGYHþMHGHMDYQLNHXYUãþDPRDVWPR SULVWDUãLKDWRSLMVNLGHUPDWLWLVLQSUHREþXWOMLYRVWQD YVDM HQ YGLKRYDQL DOHUJHQ 0HG PDQMãH GHMDYQLNH pa sodijo piskanje v prsih brez prehladne bolezni, HR]LQR¿OLMDYSHULIHUQLNUYL!LQDOHUJLMDQDSUH- KUDQVNHDOHUJHQH$/75NRWHGLQR]GUDYLOR navadno predpišemo otrokom z ne povsem zaneslji-šemo otrokom z ne povsem zaneslji- otrokom z ne povsem zaneslji- YRGLDJQR]RDVWPD7RVRQDYDGQRPODMãLRWURFL VSRJRVWLPLHSL]RGDPLSLVNDQMDYGLKDOLKVSURåHQL- PL]YLUXVQLPLRNXåEDPLSULþHPHUQHL]SROQMXMHMR YVHKGRGDWQLKPHULO]DSR]LWLYQRYUHGQRVW$3, 3ULRWURFLKVPRVH]DXYHGER]GUDYOMHQMD RGORþLOL QD SRGODJL SR]LWLYQH YUHGQRVWL$3, SUL RWURFLKSDVPRVH]D]GUDYOMHQMH]$/75RG- ORþLOLJOHGHQD]QDþLOQRNOLQLþQRVOLNRLQSRJRVWRVW SRVODEãDQM þHSUDY QLVR L]SROQMHYDOL YVHK GLDJQRþHSUDY QLVR L]SROQMHYDOL YVHK GLDJQR niso izpolnjevali vseh diagno-
VWLþQLK PHULO 3UL RWURN VPR VH ]D ]GUDYOMH- QMH]$/75QDPHVWR],*.RGORþLOLYQH]LPVNLK PHVHFLKRWURNMHLPHORGRND]DQRDOHUJLMRRG WHK VNRUDM QD LQKDODFLMVNH DOHUJHQH þHSUDY MHELODPHGLDQDVWDURVWLQDãLKRWURNOHWD6DPR GYDRWURNDVWDLPHODGRND]DQRDOHUJLMRL]NOMXþQRQD prehranski alergen in hkrati tudi povišane vrednosti HR]LQR¿OFHYYNUYLL]SROQMHQLGYHPDQMãLPHULOL 6DPRSULRGVWRWNLKMHDVWPRLPHOHGHQRGVWDU- ãHY NDU MH PDQM NRW RELþDMQR VDM QDM EL VH DVWPD SRMDYOMDODYGUXåLQDKYNDU6NRUDMRWURN MH LPHOR RSUHGHOMHQLK YVDM GYD DOL YHþ GHMDYQLNRY WYHJDQMDNDUNDåHQDYHþMR]DQHVOMLYRVWSRVWDYOMHQH GLDJQR]H7DEHOD
.HU VR RWURFL ] LQWHUPLWHQWQR DVWPR YHþLQR þDVD EUH]VLPSWRPRYODKNRXYHGED$/75RESUYLK]QD- NLKSRVODEãDQMDSRPHQLSRPHPEQRNOLQLþQRLQFH- novno ugodnejšo alternativo v okviru zdravljenja DVWPH ýH starši sami uvedejo zdravljenje ob prvih znakih poslabšanja in ga ob koncu ukinejo, SUHMHPDMRRWURFL]GUDYLORYSRYSUHþMXGQLQDOHWR LQQHNRWSUL,*.NDUMHGRGDWQDSUHGQRVW]D FHORWQRGUXåLQRLQQLåMLVWURãHN]D]GUDYVWYHQREOD- JDMQRýHSUDYVRVLPSWRPLDVWPHODKNREODJLDOL jih med poslabšanji sploh ni, vnetja dihal med po- VODEãDQMLQH]GUDYLPR'ROJRURþQLKSRVOHGLFSRQD- YOMDMRþLKVHSRVODEãDQMREYLUXVQLRNXåELGLKDO]D- HQNUDWãHQHSR]QDPRYFHORWL3ULQDãLKRWURFLK VPRVH]DLQWHUPLWHQWQR]GUDYOMHQMHDVWPHRGORþLOL SULRWURFLKQDMYHþNUDW]DUDGLRGVRWQRVWL UHGNHJDSRMDYOMDQMDSRVODEãDQM9VHPRVWDOLPVPR svetovali redno jemanje zdravil v jesensko-zimskih PHVHFLKLQSUHNLQLWHY]GUDYOMHQMDSROHWL
3UHGQRVW$/75 SUHG ,*. MH PHG GUXJLP QMLKRYD ªREOLND©QDYROMRVRQDPUHþNRWJUDQXOHWDEOHWH]D åYHþHQMH LQ WDEOHWH ]DWR MLK ODKNR XVSHãQR XSRUD- EOMDPRSULRWURFLKVWDULKPHVHFHYDOLYHþ'DMHPR jih enkrat dnevno, in sicer peroralno, zato je izko- ULVWHN SUDNWLþQR =GUDYLOR RWURFL YHþLQRPD GREUR SUHQDãDMR ]DWR MLK SR RSUDYOMHQLK NOLQLþQLK UD]LVNDYDKXYUãþDPRPHGYDUQD]GUDYLOD,*.
vnašamo v obliki vpihov, ki so pri nemirnem otro-
NX WHKQLþQR ]DKWHYQL 3RWUHEXMHPR ãH SRGDOMãHN ] PDVNR]DPODMãHRGOHWDOLSRGDOMãHN]XVWQLNRP ]DVWDUHMãHRGOHW2ESUDYLOQLWHKQLNLGDMDQMDQD PHVWRGHORYDQMDSULVSHVDPR±]GUDYLOD 1DYRGLOD]DGDMDQMHVHVWDUãHP]GLMR]DKWHYQDLQSR- gosto je potrebno dajanje dvakrat, zato je kompli- DQFDVODEãD9QDãLUD]LVNDYLVRRWURFL$/75GREUR SUHQDãDOL /H SUL HQHP EROQLNX VPR PRUDOL ]DUDGL VODERVWL ]GUDYOMHQMH ]DPHQMDWL ]D ,*. .RPSOLDQ- FDSUL]GUDYOMHQMX]$/75MHELODVNRUDM=D primerjavo kompliance pri slovenskih otrocih, zdra- YOMHQLK],*.ELELORSRWUHEQRUD]LVNDYRUD]ãLULWLLQ PHGVHERMQRSULPHUMDWLVNXSLQHRWURN
,]VOHGNLGRVHGDMREMDYOMHQLKUD]LVNDYNDåHMRGDLPD
$/75GRRGVWRWQRXþLQNRYLWRVWSUL]GUDYOMHQMX DVWPHSULRWURFLK8þLQNRYLWRVW]GUDYOMH8þLQNRYLWRVW]GUDYOMHþLQNRYLWRVW]GUDYOMHzdravlje- QMDMHYHþMDSULRWURFLK]DVWPRLQDOHUJLMVNLPULQL- WLVRPNRWSULRWURFLKL]NOMXþQR]DVWPR9QDãL UD]LVNDYLMHELOR]GUDYOMHQMH]$/75XþLQNRYLWRSUL polovici YNOMXþHQLKRWURNNDUMHYVHKRWURNNL VRELOLKRVSLWDOL]LUDQLQD3HGLDWULþQLNOLQLNLYOHWLK
±]DUDGLSRVODEãDQMDDVWPH9HOLNDXþLQ- kovitost je verjetno povezana tudi z indikacijami, ]DUDGL NDWHULK VPR VH WDNãQR ]GUDYOMHQMH RGORþLOL .OMXEQL]NLPHGLDQLVWDURVWLSUHLVNRYDQFHYMHLPH- OR VNRUDM RWURN SUL NDWHULK VPR VH RGORþLOL ]D ]GUDYOMHQMH ] $/75 GRND]DQR SUHREþXWOMLYRVW na inhalacijski alergen in tako veliko verjetnost za DOHUJLMVNLULQLWLV3RPHPEQRELELORRSUHGHOLWLDOLVR
$/75XþLQNRYLWLWXGLYGDOMãHPREGREMX]DNDUER SRWUHEQRQDGDOMHYDQMHSUHGVWDYOMHQHUD]LVNDYH Glede na izsledke raziskave, ki so jo opravili Bi- VJDDUGDVVRGHODYFLQDMEL$/75]PDQMãDOLSRUDER YVHKNRUWLNRVWHURLGRY]DS SRUDER ,*.SD]DS YSULPHUMDYLVSODFH- ERP9QDãHPSUHJOHGXWHJDQHPRUHPRSULPHU- jati, saj bi morali preveriti, kolikšna je bila poraba kortikosteroidov pri otrocih, ki smo jim ob odpustu XYHGOL]GUDYOMHQMH],*.DOLNRPELQDFLMR]GUDYLO
=$./-8ý(.
$/75 VR ODKNR ]GUDYLOR SUYH L]ELUH ]D ]GUDYOMH- nje blage astme, saj nudijo blag bronhoprotektivni XþLQHNLQ]PDQMãXMHMRYQHWMHYGLKDOQLKSRWHK±
ýLPQLåMDMHotrokova starost, tem boljši odziv ODKNRSULþDNXMHPR3ULRGORþDQMXR]GUDYOMHQMX RWURND]DVWPR]$/75VHY6OXåEL]DSOMXþQHER- OH]QLQD3HGLDWULþQLNOLQLNLY/MXEOMDQLRSLUDPRQD PHGQDURGQRVSUHMHWHVPHUQLFH=D]GUDYOMHQMH]
$/75VHQDYDGQRRGORþLPR
pri mlajših otrocih s pogostimi epizodami pi- VNDQMDSRYH]DQLPL]YLUXVQLPLRNXåEDPLVDM QDM EL ] XSRUDER$/75 ]PDQMãDOL ãWHYLOR SR- VODEãDQMSUHGYVHPSULRWURFLKVWDULK±OHW
NRMHGLDJQR]DDVWPDPDQM]DQHVOMLYDR]QLVR izpolnjena vsa merila za postavitev diagnoze DVWPD PHGWHP NR REMHNWLYQR WHVWLUDQMH PH- WDKROLQVNLDOLEURQKRGLODWDWRUQLWHVWQLPRåQR
NRVHVWDUãLQHVWULQMDMR]XYHGER,*.R]NR RFHQLPR GD ,*. RWURN QDMYHUMHWQHMH QH ER SUHMHPDO
šolskim otrokom z blago intermitentno astmo in alergijskim rinitisom VDM QDM EL $/75 ]PDQMãDOL REVWUXNFLMR GLKDOQLK SRWL ]QLåDOL porabo ȕ-DJRQLVWRY ãWHYLOR QRþQLK ]EXMDQM in število poslabãDQM
NRWGRGDWHNQL]NLPRGPHUNRP,*.þH]GUDþH]GUDzdra- YOMHQMH VDPR ] ,*. QH L]EROMãD VLPSWRPRY astme, saj je mehanizem delovanja omenjenih ]GUDYLOUD]OLþHQLQNRPSOHPHQWDUHQVWRSQMD ]GUDYOMHQMDDVWPH
3ULSRURþDPRLQWHUPLWHQWQR]GUDYOMHQMHVWDUãLXYHþDPRLQWHUPLWHQWQR]GUDYOMHQMHVWDUãLXYHPRLQWHUPLWHQWQR]GUDYOMHQMHVWDUãLXYH- GHMR$/75RESUYLK]QDNLKSUHKODGQHEROH]QLLQMLK XNLQHMR RE NRQFX EROH]QL RE QHXþLQNRYLWRVWL SD NRQWLQXLUDQR]GUDYOMHQMH5HGQRMHPDQMH$/75SUL- SRURþDPRWXGLYVHPRWURNRP]L]UD]LWRQHQDGQLPL poslabšanji in pri vseh bolnikih s pogostimi pona- YOMDMRþLPLVHSUHKODGQLPLEROH]QLPLNRVWDUãLQLVR
SUHSULþDQLNGDM]GUDYOMHQMHXYHVWLR]XNLQLWL.HU VR SRVODEãDQMD YHþLQRPD VH]RQVND VYHWXMHPR GD otroci zdravila prejemajo v delu leta s pogostejšimi VLPSWRPLLQSRVODEãDQMLPomembno je, da ob pred- SLVX$/75þH]QHNDMWHGQRYRFHQLPRXþLQNRYLWRVW ]GUDYOMHQMDLQREQMHQLRGVRWQRVWLR]PDMKQLXþLQNR- YLWRVWL]GUDYLORXNLQHPRDOLJD]DPHQMDPR
$/75 VR YDUQD QHVWHURLGQD ]GUDYLOD SULPHUQD ]D peroralno zdravljenje blage astme, predvsem pri mlajših otrocih, pri osebah s slabo komplianco pri ]GUDYOMHQMXLQSULYVHKEROQLNLK]L]UDåHQLPLQHåH- OHQLPL XþLQNL ,*. DOL QL]NR UDVWMR 6ODED SOMXþQD funkcija in neuspeãQRVW$/75SUL zdravljenju astme ]DKWHYDWDXSRUDER,*.
/,7(5$785$
5REHUWVRQ &) 3ULFH ' +HQU\ 5 0HOOLV &
*ODVJRZ 1 )LW]JHUDOG ' HW DO 6KRUW&RXUVH Montelukast for intermittent asthma in chil- GUHQ $ 5DQGRPL]HG &RQWUROOHG 7ULDO $P - 5HVS&LW&DUH0HG
6FDSDUURWWD$'L3LOOR6$UUDQDVL05DSLQR ' HW DO 0RQWHOXNDVW YHUVXV LQKDOHG FRUWLFRMontelukast versus inhaled cortico- steroids in the management of pediatric mild SHUVLVWHQW DVWKPD 0XOWLGLVFLSOLQDU\ 5HVSLUD- WRU\0HGLFLQH
%XVK $ 0RQWHOXNDVW LQ SDHGLDWULF DVWKPD where we are now and what still needs to be GRQH" 3DHGLDWULF 5HVSLUDWRU\ 5HYLHZV
.RWQLN3LUã$3UHYHQWLYQR]GUDYOMHQMHDVWPH SULRWURNX9.ULYHF83UDSURWQLN0XU$VW- PDSULRWURNX/MXEOMDQD.DWHGUD]DSHGLDWUL- jo Medicinska fakulteta Univerze v Ljubljani,
3UDSURWQLN0'LDJQR]DLQYRGHQMHDVWPHSUL RWURNX PODMãHP RG OHW 9 .ULYHF 8 3UD- SURWQLN 0 XU $VWPD SUL RWURNX /MXEOMDQD .DWHGUD ]D SHGLDWULMR 0HGLFLQVND IDNXOWHWD 8QLYHU]HY/MXEOMDQL
%LVJDDUG + =LHOHQ 6 /X] *DUFLD*DUFLD 0 -RKQVWRQ 6/ *LOOHV / 0HQWHQ - HW DO 0RQ-
WHOXNDVWUHGXFHVDVWKPDH[DFHUEDWLRQVLQWR
\HDUROGFKLOGUHQZLWKLQWHUPLWWHQWDVWKPD
$P-5HVS&ULW&DUH0HG *OREDO,QLWLDWLYHIRU$VWKPD*OREDO6WUDWHJ\
IRU$VWKPD0DQDJHPHQWDQG3UHYHQWLRQ
$YDLODEOHIURPZZZJLQDVWPDRUJ
.ULYHF 8 3LVNDQMH Y SUVLK Y SUHGãROVNHP REGREMX ± IHQRWLSL DVWPH 9 .ULYHF 8 3UD- SURWQLN 0 XU $VWPD SUL RWURNX /MXEOMDQD .DWHGUD ]D SHGLDWULMR 0HGLFLQVND IDNXOWHWD 8QLYHU]HY/MXEOMDQL
/DX65ROHRIDOOHUJHQH[SRVXUHRQWKHGHYH- ORSPHQW RI DVWKPD LQ FKLOGKRRG ,Q &DUOVHQ .+*HUULWVHQ-HGV3DHGLDWULFDVWKPD6KHI-
¿HOG(56
2EHU&+RIMDQ6$VWKPDJHQHWLFVWKH ORQJDQGZLQGLQJURDGWRJHQHGLVFRYHU\*H- QHVDQG,PPXQLW\
-DUYLV%0DUNKDP$0RQWHOXNDVWDUHYLHZRI LWV WKHUDSHXWLF SRWHQWLDO LQ SHUVLVWHQW DVWKPD 'UXJV
.QRUU%)UDQFKL/0%LVJDDUG+9HUPHXOHQ -+ /H6RXHI 3 6DQWDQHOOR 1 HW DO 0RQWHOX- kast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged WR\HDUV3HGLDWULFV(
6WUDXE '$ 0LQRFFKLHUL 6 0RHOOHU$ +DP- DFKHU-:LOGKDEHU-+7KHHIIHFWRIPRQWHOX- NDVWRQH[KDOHGQLWULFR[LGHDQGOXQJIXQFWLRQ LQ DVWKPDWLF FKLOGUHQ WR \HDUV ROG &KHVW
6WUDXE '$ 0RHOOHU$ 0LQRFFKLHUL 6 +DP- DFKHU - 6HQQKDXVHU )+ +DOO */ HW DO 7KH HIIHFWRIPRQWHOXNDVWRQOXQJIXQFWLRQDQGH[- KDOHGQLWULFR[LGHLQLQIDQWVZLWKHDUO\FKLOG- KRRGDVWKPD(XU5HVSLU- 6]HÀHU 6- 3KLOOLSV %5 0DUWLQH] )' &KLQ- FKLOOL 90 /HPDQVNH 5) 6WUXQN 5& HW DO Characterization of within-subject responses WR ÀXWLFDVRQH DQG PRQWHOXNDVW LQ FKLOGKRRG DVWKPD - $OOHUJ\ &OLQ ,PPXQRO
&RNHU&(UED\UDNWDU=(YDOXDWLRQRIPRQWH- OXNDVW LQ WR \HDU ROG FKLOGUHQ ZLWK PLOG
persistent asthma and compared with inhaled FRUWLFRVWHURLGV$OOHUJRO ,PPXQRSDWKRO
6LPRQV)(9LOOD-5/HH%:7HSHU$0/\W- WOH%$ULVWL]DEDO*HWDO0RQWHOXNDVWDGGHGWR budesonide in children with persistent asthma:
DUDQGRPL]HGGRXEOHEOLQGFURVVRYHUVWXG\- 3HGLDWU
.RQWDNWQDRVHED&RQWDFWSHUVRQ
$VLVW$QD.RWQLN3LUãGUPHG 6OXåED]DSOMXþQHEROH]QL 3HGLDWULþQDNOLQLND
8QLYHU]LWHWQLNOLQLþQLFHQWHU/MXEOMDQDLQ .DWHGUD]DSHGLDWULMR
Medicinska fakulteta Univerza v Ljubljani
%RKRULþHYD /MXEOMDQD
(SRãWDDQDNRWQLNSLUV#NFOMVL 3ULVSHOR5HFHLYHG 6SUHMHWR$FFHSWHG
